HealthDay News — Subthalamic deep brain stimulation (DBS) is an effective long-term therapy for Parkinson disease (PD), according to a study published online September 15 in JAMA Neurology.

Afrezza is a rapid-acting inhaled human insulin that is currently approved to improve glycemic control in adults with diabetes mellitus.

BPL-003 is a novel, nasal spray formulation of mebufotenin benzoate designed to deliver rapid and durable antidepressant effects from a single dose.

HealthDay News — Overdose deaths in older adults from fentanyl mixed with stimulants, such as cocaine and methamphetamine, have surged in the past 8 years, according to a study presented at the annual ...

Iptacopan, an oral factor B inhibitor, previously received accelerated approval in 2024 under the brand name Fabhalta for IgAN, specifically to reduce proteinuria in patients at risk of rapid disease ...

Reports of local anesthetic poisonings decreased 2011 to 2022, but reports of lidocaine poisoning increased since 2010 advisories.

State health commissioner says risk to the public remains 'very low' as mosquito activity decreases with cooler temperatures.

New treatment approved for bipolar I disorder; Rinvoq IBD indications updated; blood-based test for early detection of amyloid pathology; and an oral ...

Ulixacaltamide is a highly selective small molecule T-type calcium channel inhibitor designed to block neuronal bursting in the cerebello-thalamo-cortical circuit linked to tremor activity.

Yuflyma is a TNF blocker approved as a citrate-free, high-concentration, interchangeable biosimilar to Humira (adalimumab).

The US Food and Drug Administration (FDA) announced earlier this week that the company is recalling several batches of its microwaveable rice products. Officials said the stones are naturally ...

Worse outcomes include greater clinical impairment, emotional distress, functional difficulties, and disability ...